CXCR2 and chronic obstructive pulmonary disease: The CXCR2 antagonist MK-7123 was used at various doses in a small phase 2 study including 616 patients with COPD, reporting that the highest dose of MK-7123 was able to improve FEV1 and increase the time to exacerbation, indicating a clinical benefit to patients.